Sordo-Bahamonde Christian, Lorenzo-Herrero Seila, Gonzalez-Rodriguez Ana P, Martínez-Pérez Alejandra, Rodrigo Juan P, García-Pedrero Juana M, Gonzalez Segundo
Department of Functional Biology, Immunology, Universidad de Oviedo, 33006 Oviedo, Spain.
Instituto Universitario de Oncología del Principado de Asturias (IUOPA), 33006 Oviedo, Spain.
Cancers (Basel). 2023 May 25;15(11):2912. doi: 10.3390/cancers15112912.
Chemotherapy has been the basis of advanced cancer treatment for decades. This therapy has largely been considered immunosuppressive, yet accumulated preclinical and clinical evidence shows that certain chemotherapeutic drugs, under defined conditions, may stimulate antitumor immunity and potentiate immune checkpoint inhibitor (ICI)-based therapy. Its effectiveness has been highlighted by recent regulatory approvals of various combinations of chemotherapy with ICIs in several tumors, particularly in some difficult-to-treat cancers. This review discusses the immune modulatory properties of chemotherapy and how they may be harnessed to develop novel chemo-immunotherapy combinations. It also highlights the key determinants of the success of chemo-immunotherapy and provides an overview of the combined chemo-immunotherapies that have been clinically approved.
几十年来,化疗一直是晚期癌症治疗的基础。这种疗法在很大程度上被认为具有免疫抑制作用,但越来越多的临床前和临床证据表明,某些化疗药物在特定条件下可能会刺激抗肿瘤免疫,并增强基于免疫检查点抑制剂(ICI)的治疗效果。近期化疗与ICI的多种联合疗法在几种肿瘤,尤其是一些难治性癌症中获得监管批准,凸显了其有效性。本综述讨论了化疗的免疫调节特性,以及如何利用这些特性开发新的化疗免疫联合疗法。它还强调了化疗免疫疗法成功的关键决定因素,并概述了已获临床批准的联合化疗免疫疗法。